Tumor Necrosis Detection
Tumor Necrosis Detection - Related Videos
01:16
Necrosis
0 Views •
2023
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”. Morphological Manifestations of Necrosis Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become anucleated and die, but their...
06:23
A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
0 Views •
Cited by 8 •
2017
This protocol describes the generation of murine orthotopic bladder tumors in female C57BL/6J mice and the monitoring of tumor growth.
02:12
Muscle Necrosis Assay in C. elegans Induced by a Pathogenic Aeromonas Strain
0 Views •
2026
Source: Chen, Y. et. al., Evaluating Virulence and Pathogenesis of Aeromonas Infection in a Caenorhabditis elegans Model. J. Vis. Exp. (2018)This video demonstrates a muscle necrosis assay in C. elegans (Caenorhabditis elegans) using pathogenic Aeromonas strains. By feeding green fluorescent protein (GFP)-expressing worms on Aeromonas-seeded plates, the assay models bacterial infection and reveals tissue damage through fluorescence imaging. The progressive loss of muscle structure and GFP...
01:16
Cellular Injury IV: Necrosis
0 Views •
2026
Necrosis is a form of irreversible cell death caused by severe injury such as ischemia, toxins, or trauma. Unlike programmed cell death, it is an uncontrolled, pathological process that typically provokes inflammation in surrounding tissues.Pathophysiologic ChangesNecrosis begins when cells sustain critical damage, leading to swelling of organelles, particularly mitochondria, and rapid ATP depletion. As energy levels decline, membrane ion pumps fail, leading to calcium influx and eventually,...
11:15
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
0 Views •
Cited by 8 •
2016
This manuscript describes clinical protocols for two next-generation sequencing panels. One panel interrogates hematologic malignancies while the other panel targets genes commonly mutated in solid tumors. Molecular classification of driver mutations in human malignancies offers valuable prognostic and predictive information.
FAQs
Necrosis produces several measurable signals rather than a single marker. Loss of cell membrane integrity allows intracellular components to be released, while tissue injury alters the structure of the tumor. These changes provide the biological basis for histological assessment and molecular biomarker analysis, helping investigators recognize nonviable regions and distinguish them from remaining viable tissue.
Reduced blood flow is an important accompanying feature because it marks regions that differ physiologically from better-perfused, viable tumor tissue. When interpreted alongside structural or molecular evidence, this change can strengthen identification of necrotic areas. The relationship is useful for studying how tissue injury and local tumor conditions contribute to progression and treatment response.
Histology, medical imaging, and molecular biomarkers examine tumor necrosis from complementary perspectives. Histology provides structural evidence, imaging evaluates changes across the tumor, and biomarkers reflect associated molecular or intracellular changes. No single approach necessarily captures every aspect, so combining methods can produce a more complete assessment of the distribution and extent of nonviable tissue.
A practical workflow is to identify nonviable regions, examine structural changes histologically, assess patterns with medical imaging, and evaluate relevant molecular biomarkers. Comparing results across these approaches helps characterize the extent of necrosis and separates it from viable tissue. This produces a more informative tumor assessment than relying on one biological signal alone.
It can be used to examine whether chemotherapy or radiation has produced tissue injury within a tumor. By comparing the presence and extent of necrotic regions with viable tissue, investigators can assess treatment response rather than treating the tumor as uniformly living. This supports research into treatment effectiveness and helps characterize changes after therapy.
The amount and distribution of necrotic tissue can help characterize tumor aggressiveness, disease progression, and prognosis. In biology, these observations connect local structural and molecular injury with the broader behavior of the tumor. They also provide a basis for evaluating whether observed changes are consistent with treatment-related effects, supporting interpretation of tumor status in research and oncology.